AstraZeneca reported a 100% year-on-year increase in earnings per share for Q1 of 2021, to $1.19.
The company achieved strong revenue growth of 15% in Q1 of 2021 to $7.3 billion, excluding a contribution from the pandemic vaccine COVID-19, revenue growth increased by 11% to $7.04 billion.